Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study is being conducted to meet regulatory post-marketing commitments.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to World Health Organization \[WHO 2000\] classification).
Disease progression within 12 months prior to study enrollment.
Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent.
You may not be if
Patients with poorly differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification).
Prior treatment with any tyrosine kinase inhibitors, anti vascular endothelial growth factor (VEGF) angiogenesis inhibitors, non VEGF targeted angiogenesis inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.
